<DOC>
	<DOCNO>NCT01837277</DOCNO>
	<brief_summary>The current available antiretroviral ( ARV ) agent make possible successful treatment virtually HIV-infected patient , problem relate early mortality still concern , mainly resources-limited setting . There several publish report show patient significantly high risk death first month treatment , comparison observe outcomes developed country . One consistently detect risk early mortality across report baseline low CD4 count , although seem reason outcome . In Brazil develop country , still large proportion AIDS patient diagnose AIDS , seek health care HIV infection late course disease . Raltegravir ( RAL ) , first HIV-1 integrase inhibitor , potent safe ARV drug . The available evidence suggest promotes faster decline HIV-1 plasma viremia , high increase CD4 cell count , comparison Efavirenz ( EFV ) arm . The investigator propose compare impact RAL versus EFV early mortality rate severely ill ( CD4+ cell count &lt; 50 cells/mm3 ) patient start ARV therapy .</brief_summary>
	<brief_title>Impact Raltegravir-based Regimen Early Mortality Severely Immunocompromised AIDS Patients</brief_title>
	<detailed_description />
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients confirm HIV1 infection ( positive Western blot plasma HIV1 RNA &gt; 1,000 copies/ml ) No previous use ARV drug ( drugnaïve patient ) Presence clinical symptom accord Rio de Janeiro / Caracas´ AIDS definition ( Asthenia , Cachexia/Wasting , Cough , Dermatitis , persistent , Diarrhea , Fever , Lymphadenopathy , Candidiasis , oral , hairy leukoplasia , Central nervous system dysfunction , Herpes zoster individual young 60 year age ) ) , and/or active AIDSdefining condition Baseline CD4+ cell count equal low 50 cells/mm3 Age equal high 18 year HIV1 plasma viral load ≥ 1,000 copy HIV1 RNA/ml Undetectable plasma viral load screen CD4 cell count &gt; 50 cells/mm3 Asymptomatic individual</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>